Home › Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients
 

Keywords :   


Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

2014-07-25 12:09:31| Chemicals - Topix.net

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary , today announced that an investigational Phase 3 trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival .

Tags: meet primary trial phase

Category:Chemicals

Latest from this category

All news
27.11 Pflaumer Brothers Named 2024 Company of the Year by the Metropolitan New York Coatings Association
27.11Jotun Discusses Shipping\'s Climate Role and Biodiversity at COP29
27.11 PPG Announces 50th Order for Electrostatic Marine Coating Application
26.11ROSS VersaMix Multi Shaft Mixers are for Complex Formulations
26.11PPG Completes Sale of Silicas Products Business to QEMETICA
26.11¦nie¿ka Among Leaders of Sustainable Development in Poland
26.11Solvay Unveils Climate and Water Projects in Brazil with HRH Princess Astrid of Belgium
25.11PPG Recognized in Newsweeks Americas Greenest Companies List
Chemicals »
27.11 ( #1670 )
27.1117 AIR AGS 83M-S
27.11 XYZ 3
27.11XVSecret1
27.11NFT ADVANCE 3-370!
27.11 101
27.11
27.11 DESCENTE L
More »